IP Library › Granted Patent US 12,239,743
Granted Patent B2
US 12,239,743 · App. 17/402,222 · Granted Mar 4, 2025

Dynamic bio-nanoparticle platforms

Inventors: Franco Vitaliano (Boston, MA); Gordana Dragan Vitaliano (Boston, MA)
Assignee: METAQOR LLC
A61K9/5169A61K9/5068
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,239,743
App. No.
17/402,222
Granted
Mar 4, 2025
Kind
B2
Abstract

The invention in suitable embodiments is directed to dynamic bio-nanoparticle elements and bio-nanoparticle platforms employing such bio-nanoparticle elements. In one aspect, one or more elements of one or more types, formed from isolated, synthetic and or recombinant amino acid residues comprising in whole or in part one or more types of Clathrin and or Coatomer I/II proteins of one or more isoforms, execute one or more functions and or effect one or more ends, in vivo and or in vitro.

Claims (8)

1. A composition comprising: 1) a human clathrin triskelion and 2) a therapeutic and/or diagnostic agent, wherein the human clathrin triskelion consists of (i) 3 isolated clathrin heavy chain (CHC) proteins and (ii) 3 isolated clathrin light chain (CLC) proteins, wherein the human clathrin triskelion is linked to the therapeutic and/or diagnostic agent, and wherein the CHC is linked to one or more biodegradable controlled-release polymers.

2. The composition of claim 1 , wherein the human clathrin triskelion is linked to a monoclonal antibody.

3. The composition of claim 1 , wherein the therapeutic and/or diagnostic agent is an agent for treating Parkinson's, multiple sclerosis, epilepsy, meningitis, cancer, or Alzheimer's disease.

4. The composition of claim 1 , wherein the therapeutic and/or diagnostic agent modifies one or more cellular processes selected from the group consisting of: endocytosis, exocytosis, mitosis, cellular trafficking, and cellular signaling.

5. The composition of claim 1 , wherein the composition does not comprise an adaptor protein.

6. The composition of claim 1 , wherein the CHC is linked to the therapeutic and/or diagnostic agent via polyethylene glycol (PEG), biotin-avidin interaction, cross-linking, or covalent bonding.

7. The composition of claim 1 , wherein the CHC is linked to one or more targeting moieties.

8. The composition of claim 7 , wherein the one or more targeting moieties comprises antibodies, peptides, fluorophores, permeation enhancers, amino sugars, lipoproteins, toxins, transferrin, and glycoproteins.

Assignments (2)
CHANGE OF NAME Recorded Dec 16, 2025
From: METAQOR LLC
To: METAQOR INC.
Reel/Frame 073994/0780 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2021
From: VITALIANO, FRANCO; VITALIANO, GORDANA
To: METAQOR LLC
Reel/Frame 057177/0241 →
Continuity (3)
Continuation 13847058 · Mar 19, 2013
Continuation 12399906 · Mar 6, 2009
Related Publication 20220047520A1 · Feb 17, 2022
References Cited (400)
US 4522811A · Eppstein et al. · 1985 [cited by applicant]
US 5145684A · Liversidge et al. · 1992 [cited by applicant]
US 5427767A · Kreese et al. · 1995 [cited by applicant]
US 5989859A · Bandman et al. · 1999 [cited by applicant]
US 6270806B1 · Liversidge et al. · 2001 [cited by applicant]
US 6277142B1 · Pinter · 2001 [cited by applicant]
US 6437413B1 · Yamguchi et al. · 2002 [cited by applicant]
US 6456994B1 · Tucci · 2002 [cited by applicant]
US 6459097B1 · Zagpslom · 2002 [cited by applicant]
US 6472681B1 · Kane · 2002 [cited by applicant]
US 6756039B1 · Yeates et al. · 2004 [cited by applicant]
US 7033834B2 · Valerio et al. · 2006 [cited by applicant]
US 7037520B2 · Smyth Templeton · 2006 [cited by applicant]
US 7048949B2 · Silgar et al. · 2006 [cited by applicant]
US 7060291B1 · Meers et al. · 2006 [cited by applicant]
US 7063860B2 · Chancellor et al. · 2006 [cited by applicant]
US RE39229E · Choo et al. · 2006 [cited by applicant]
US 7094409B2 · Bachmann et al. · 2006 [cited by applicant]
US 7101532B2 · Aikawa et al. · 2006 [cited by applicant]
US 7101570B2 · Hope et al. · 2006 [cited by applicant]
US 7105303B2 · Ralston et al. · 2006 [cited by applicant]
US 7108863B2 · Zalipsky et al. · 2006 [cited by applicant]
US 7108915B2 · Adams et al. · 2006 [cited by applicant]
US 7112330B1 · Buonamassa et al. · 2006 [cited by applicant]
US 7112337B2 · Huang et al. · 2006 [cited by applicant]
US 7113967B2 · Cleve et al. · 2006 [cited by applicant]
US 7118738B2 · Schlom et al. · 2006 [cited by applicant]
US 7118740B1 · Russell et al. · 2006 [cited by applicant]
US 7151789B2 · Jette et al. · 2006 [cited by applicant]
US 7170142B2 · Wojcik et al. · 2007 [cited by applicant]
US 7216038B2 · Vitaliano · 2007 [cited by applicant]
US 7217692B2 · Climent-Johansson · 2007 [cited by applicant]
US 7219017B2 · Vitaliano · 2007 [cited by applicant]
US 7219018B2 · Vitaliano · 2007 [cited by applicant]
US 7268116B2 · Liang · 2007 [cited by applicant]
US 7291598B2 · Sung et al. · 2007 [cited by applicant]
US 7348030B1 · Sung et al. · 2008 [cited by applicant]
US 7393924B2 · Vitaliano et al. · 2008 [cited by applicant]
US 7404969B2 · Chen et al. · 2008 [cited by applicant]
US 7413727B2 · Klaveness et al. · 2008 [cited by applicant]
US 7417119B2 · Lincoln · 2008 [cited by applicant]
US 7419654B2 · Dewanjee · 2008 [cited by applicant]
US 7431915B2 · Jiang et al. · 2008 [cited by applicant]
US 7449200B2 · Sung et al. · 2008 [cited by applicant]
US 7452551B1 · Unger et al. · 2008 [cited by applicant]
US 7473531B1 · Domon et al. · 2009 [cited by applicant]
US 7498177B2 · De La Fuente et al. · 2009 [cited by applicant]
US 7842466B1 · Kim et al. · 2010 [cited by applicant]
US 8081850B2 · Beuasoleil et al. · 2011 [cited by applicant]
US 8263358B2 · Clark · 2012 [cited by applicant]
US 8901284B2 · Vlassov et al. · 2014 [cited by applicant]
US 11096901B2 · Vitaliano · 2021 [cited by examiner]
US 11235062B2 · Vitaliano et al. · 2022 [cited by applicant]
US 20040155184A1 · Stockman et al. · 2004 [cited by applicant]
US 20040253138A1 · Malak · 2004 [cited by applicant]
US 20060121016A1 · Lee · 2006 [cited by applicant]
US 20060159692A1 · Taya · 2006 [cited by applicant]
US 20070141163A1 · Vitallano · 2007 [cited by applicant]
US 20070253051A1 · Ishihara et al. · 2007 [cited by applicant]
US 20070273959A1 · Lawandy et al. · 2007 [cited by applicant]
US 20090011008A1 · Sung et al. · 2009 [cited by applicant]
US 20090028956A1 · Slager et al. · 2009 [cited by applicant]
US 20090047300A1 · Ablrob et al. · 2009 [cited by applicant]
US 20090048331A1 · Soon-Shiong et al. · 2009 [cited by applicant]
US 20100226856A1 · Vitaliano · 2010 [cited by applicant]
US 20120263793A1 · Vitaliano · 2012 [cited by applicant]
US 20140288192A1 · Vitaliano et al. · 2014 [cited by applicant]
US 20160060309A1 · Vitaliano et al. · 2016 [cited by applicant]
US 20160143992A1 · Vitaliano et al. · 2016 [cited by applicant]
US 20160158313A1 · Vitaliano et al. · 2016 [cited by applicant]
US 20160158367A1 · Vitaliano et al. · 2016 [cited by applicant]
US 20160178652A1 · Vitaliano et al. · 2016 [cited by applicant]
US 20160158366A1 · Vitaliano et al. · 2016 [cited by applicant]
US 20160310616A1 · Vitaliano et al. · 2016 [cited by applicant]
US 20170014475A1 · Vitaliano et al. · 2017 [cited by applicant]
US 20170014511A1 · Vitaliano et al. · 2017 [cited by applicant]
US 20170165324A1 · Vitaliano et al. · 2017 [cited by applicant]
US 20170202784A1 · Vitaliano et al. · 2017 [cited by applicant]
US 20180185518A1 · Vitaliano et al. · 2018 [cited by applicant]
US 20180207106A1 · Vitaliano et al. · 2018 [cited by applicant]
US 20180256510A1 · Vitaliano et al. · 2018 [cited by applicant]
US 20180256511A1 · Vitaliano et al. · 2018 [cited by applicant]
US 20210353771A1 · Vitaliano · 2021 [cited by examiner]
US 20230293722A1 · Vitaliano et al. · 2023 [cited by applicant]
WO 1991001732A1 · 1991 [cited by applicant]
WO WO199101732 · 1991 [cited by applicant]
WO 1992006180A1 · 1992 [cited by applicant]
WO WO1999041373 · 1999 [cited by applicant]
WO WO2003009814 · 2003 [cited by applicant]
WO WO2003016475 · 2003 [cited by applicant]
WO WO2003040301 · 2003 [cited by applicant]
WO WO2003064467 · 2003 [cited by applicant]
WO WO2004001019 · 2003 [cited by applicant]
WO WO2004076483 · 2004 [cited by applicant]
WO WO2004078112 · 2004 [cited by applicant]
Albrecht et al., “Trophic factors in cerebrospinal fluid and spinal cord of patients with tropical spastic paraparesis, HIV, and Creutzfeldt-Jakob disease,” AIDS Research and Human Retroviruses, Mar. 2006, 22(3):248-254. [cited by applicant]
Andero et al., “BDNF-TrkB receptor regulation of distributed adult neural plasticity, memory formation, and psychiatric disorders,” Progress in Molecular Ciology and Translational Science, 2014, 122:169-192. [cited by applicant]
Ando et al., “Animal model of dementia induced by entorhinal synaptic damage and partial restoration of cognitive deficits by BDNF and carnitine,” J. Neurosci. Res., Oct. 2002, 70(3):519-527. [cited by applicant]
Anthony et al., “Influence of HAART on HIV-related CNS disease and neuroinflammation,” Journal of Neuropathology and Experimental Neurology, Jun. 2005, 64(6):529-536. [cited by applicant]
Antunes et al., “The novel object recognition memory: neurobiology, test procedure, and its modifications,” Cognitive Processing, 2012, 13:93-110. [cited by applicant]
Aprea et al., “Tubulin-mediated binding of human immunodeficiency virus-1 Tat to the cytoskeleton causes proteasomal-dependent degradation of microtubule-associated protein 2 and neuronal damage,” The Journal of Neurosc… [cited by applicant]
Baba et al., “Clathrin-dependent and clathrin-independent endocytosis are differentially sensitive to insertion of poly (ethylene glycol)-derivatized cholesterol in the plasma membrane, ” Traffic, 2001, 2:501-512. [cited by applicant]
Bachis et al., “Human immunodeficiency virus type 1 alters brain-derived neurotrophic factor processing in neurons” The Journal of Neuroscience, Jul. 2012, 32(28):9477-9484. [cited by applicant]
Bamji et al., “BDNF mobilizes synaptic vesicles and enhances synapse formation by disrupting cadherin-beta-catenin interactions,” The Journal of Cell Biology, 2006, 174(2):289-299. [cited by applicant]
Barde et al., “Purification of a new neurotrophic factor from mammalian brain,” The EMBO Journal, 1982, 1:549-553. [cited by applicant]
Barnes et al., “Proteolysis of proBDNF is a key regulator in the formation of memory,” PloS Sep. 1, 2008, 3(9):e3248, 11 pages. [cited by applicant]
Bartus et al., “Clinical tests of neurotrophic factors for human neurodegenerative diseases, part 1: Where have we been and what have we learned?,” Neurobiology of Disease, Jan. 2017, 97(Pt B):156-168. [cited by applicant]
Bekinschtein et al., “BDNF and memory processing,” Neuropharmacology, Jan. 2014, 76(Pt C): 677-683. [cited by applicant]
Bekinschtein et al., “BDNF is essential to promote persistence of long-term memory storage,” PNAS USA, Feb. 2008, 105(7):2711-2716. [cited by applicant]
Blurton-Jones et al., “Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease, ” PNAS SA, Aug. 2009, 106(32):13594-13599. [cited by applicant]
Boado et al., “Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood-brain barrier,” Biotechnology and bioengineering,… [cited by applicant]
Brunet et al., “Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway,” Current Opinion in Neurobiology, Jun. 2001, 11(3):297-305. [cited by applicant]
Caceres et al., “Immunocytochemical localization of tubulin and microtubule-associated protein 2 during the development of hippocampal neurons in culture,” The Journal of Neuroscience, Mar. 1986, 6(3):714-722. [cited by applicant]
Chartoff et al., “Behavioral and molecular effects of dopamine D1 receptor stimulation during naloxone-precipitated morphine withdrawal,” The Journal of neuroscience, Jun. 2006, 26(24):6450-6457. [cited by applicant]
Chen et al., “Focused ultrasound-enhanced intranasal brain delivery of brain-derived neurotrophic factor,” Scientific reports, Jun. 2016, 6(28599):1-8. [cited by applicant]
Clifford et al., “HIV-Associated Neurocognitive Disorder (HAND),” Lancet Infect. Dis., Nov. 2013, 13(11):976-986. [cited by applicant]
Cunha et al., “A simple role for BDNF in learning and memory?,” Frontiers in Molecular Neuroscience, Feb. 2010, 3, 1 (2010). [cited by applicant]
Dickens et al., “Chronic low-level expression of HIV-1 Tat promotes a neurodegenerative phenotype with aging,” Sci. Rep., Aug. 2017, 7(7748):1-11. [cited by applicant]
Dingwall et al., “Human immunodeficiency virus 1 tat protein binds trans-activation-responsive region (TAR) RNA in vitro,” PNAS USA, Sep. 1989, 86, 6925-6929. [cited by applicant]
Fan et al., “HIV Tat Impairs Neurogenesis through Functioning as a Notch Ligand and Activation of Notch Signaling Pathway,” The Journal of Neuroscience, Nov. 2016, 36(44):11362-11373. [cited by applicant]
Fassnacht et al., “AKT is highly phosphorylated in pheochromocytomas but not in benign adrenocortical tumors,” J. Clin. Endocrinol. Metab., Jul. 2005, 90(7):4366-4370. [cited by applicant]
Fatima et al., “Tripartite containing motif 32 modulates proliferation of human neural precursor cells in HIV-1 neurodegeneration,” Cell Death and Differentiation, Nov. 2015, 23: 776-786. [cited by applicant]
Fields et al., “HIV-1 Tat alters neuronal autophagy by modulating autophagosome fusion to the lysosome: implications for HIV-associated neurocognitive disorders,” The Journal of neuroscience, Feb. 2015, 35,(5):921-1938. [cited by applicant]
Fitting et al., “Interactive comorbidity between opioid drug abuse and HIV-1 Tat: chronic exposure augments spine loss and sublethal dendritic pathology in striatal neurons,” The American Journal of Pathology, Sep. 2010… [cited by applicant]
Fujimura et al., “HIV-1 proviral DNA load across neuroanatomic regions of individuals with evidence for HIV-1-associated dementia,” Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology :, Nov. 1997, 1… [cited by applicant]
Geral et al., “From molecular to nanotechnology strategies for delivery of neurotrophins: emphasis on brain-derived neurotrophic factor (BDNF),” Pharmaceutics, Feb. 2013, 5(1):127-167. [cited by applicant]
Gomez et al., “Intranasal treatment of neurodegenerative diseases and stroke,” Frontiers in Bioscience, Jan. 2012, 4:74-89. [cited by applicant]
Granseth et al., “Clathrin-mediated endocytosis: the physiological mechanism of vesicle retrieval at hippocampal synapses,” The Journal of Physiology, 2007, 585(3):681-686. [cited by applicant]
Green et al., “Adapt to Neurotoxic HIV Protein Tat Downstream of a GluN2A-Ubiquitin Ligase Signaling Pathway,” The Journal of Neuroscience, Dec. 2016, 36(50): 12640-12649. [cited by applicant]
Hahn et al., “Effects of chronic HIV-1 Tat exposure in the CNS: heightened vulnerability of males versus females to changes in cell numbers, synaptic integrity, and behavior,” Brain Structure and Function, Dec. 2015, 22… [cited by applicant]
Henderson et al., “Presence of Tat and transactivation response element in spinal fluid despite antiretroviral therapy,” Aids, Dec. 2019, 33(Suppl 2):S145-S157. [cited by applicant]
Horch et al., “BDNF release from single cells elicits local dendritic growth in nearby neurons,” Nature Neuroscience, Sep. 2002, 5:1177-1184. [cited by applicant]
Hudson et al., “Detection of the human immunodeficiency virus regulatory protein tat in CNS tissues,” Journal of Neurovirology, Jul. 2009, 6(2):145-155. [cited by applicant]
Jaeger et al., “Modeling HIV-associated neurocognitive disorders in mice: new approaches in the changing face of HIV neuropathogenesis,” Disease Models & Mechanisms, May 2012, 5(3):313-322. [cited by applicant]
Jones et al., “Intraventricular injection of human immunodeficiency virus type 1 (HIV-1) tat protein causes inflammation, gliosis, apoptosis, and ventricular enlargement,” Journal of Neuropathology and Experimental Neur… [cited by applicant]
Khalin et al., “Brain-derived neurotrophic factor delivered to the brain using poly (lactide-co-glycolide) nanoparticles improves neurological and cognitive outcome in mice with traumatic brain injury,” Drug Delivery, 2… [cited by applicant]
Khuchua et al., “Deletion of the N-terminus of murine map2 by gene targeting disrupts hippocampal ca1 neuron architecture and alters contextual memory,” Neuroscience, Jun. 2003, 11(1):101-111. [cited by applicant]
Kim et al., “Neuropathologies in transgenic mice expressing human immunodeficiency virus type 1 Tat protein under the regulation of the astrocyte-specific glial fibrillary acidic protein promoter and doxycycline,” The A… [cited by applicant]
Kirchhausen et al., “Molecular structure, function, and dynamicsof clathrin-mediated membrane traffic,” Cold Spring Harb Perspect Biol., 2014, 6(a016725), 28 pages. [cited by applicant]
Kuipers et al., “BDNF-induced LTP is associated with rapid Arc/Arg3.1-dependent enhancement in adult hippocampal neurogenesis,” Scientific Reports, 2016, 6(21222):-1-14. [cited by applicant]
Lee et al., “Regulation of cell survival by secreted proneurotrophins,” Science, 294(5548):1945-1948. [cited by applicant]
Lu et al., “BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases,” Nature Reviews Neuroscience, May 2013, 14:401-416. [cited by applicant]
Maragos et al., “Neuronal injury in hippocampus with human immunodeficiency virus transactivating protein, Tat,” Neuroscience, Mar. 2003, 1179(1):43-53. [cited by applicant]
Mattson et al., “BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders,” Trends in Neurosciences, Oct. 2004, 27(10):589-594. [cited by applicant]
Melo et al., “Spatiotemporal resolution of BDNF neuroprotection against glutamate excitotoxicity in cultured hippocampal neurons,” Neuroscience, 2013, 237:66-86. [cited by applicant]
Meyers and W. Miller, “Optimal alignments in linear space,” CABIOS, Mar. 1988, 4(1):11-17. [cited by applicant]
Mills, The interplay between clathrin-coated vesicles and cell signalling. Seminars in cell & developmental biology 18, 459-470 (2007). [cited by applicant]
Mishra et al., “Human immunodeficiency virus type 1 Tat modulates proliferation and differentiation of human neural precursor cells: implication in NeuroAIDS,” Journal of neurovirology, 2010, 16:355-367. [cited by applicant]
Mizunoet al., “Phosphatidylinositol 3-kinase: a molecule mediating BDNF-dependent spatial memory formation,” Molecular Psychiatry, 2003, 8:217-224. [cited by applicant]
Mocchetti et al., “Implementing neuronal plasticity in NeuroAIDS: the experience of brain-derived neurotrophic factor and other neurotrophic factors,” Journal of neuroimmune pharmacology : the official journal of the So… [cited by applicant]
Nagahara et al., “Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease,” Nat. Med., 2009, 15:331-337. [cited by applicant]
Needleman and Wunsch, “A general method applicable to the search for similarities in the amino acid sequence of two proteins.,” J. Mol. Biol., Mar. 1970, 48:444-453. [cited by applicant]
Nir et al., “Association of Immunosuppression and Viral Load with Subcortical Brain Volume in an International Sample of People Living With HIV,” JAMA Network, Jan. 2021,, e2031190, 15 pages. [cited by applicant]
Numakawa et al., “Actions of Brain-Derived Neurotrophin Factor in the Neurogenesis and Neuronal Function, and Its Involvement in the Pathophysiology of Brain Diseases,” International journal of molecular sciences, 2018,… [cited by applicant]
Numakawa et al., “BDNF function and intracellular signaling in neurons,” Histology and Histopathology, 2010, 25:237-258. [cited by applicant]
Panja et al., “BDNF mechanisms in late LTP formation: A synthesis and breakdown,” Neuropharmacology, 2014, 76(Pt C):664-676. [cited by applicant]
Pardridge et al., “Transport of human recombinant brain-derived neurotrophic factor (BDNF) through the rat blood-brain barrier in vivo using vector-mediated peptide drug delivery,” Pharmaceutical Research, 1994, 11:738-… [cited by applicant]
Paterson et al., “The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings,” Brain, Oct. 2020, 143(10):3104-3120. [cited by applicant]
Patterson et al., “Recombinant BDNF rescues deficits in basal synaptic transmission and hippocampal LTP in BDNF knockout mice,” Neuron, 1996, 16:1137-1145. [cited by applicant]
Preston et al., “Transcytosis of macromolecules at the blood-brain barrier,” Advances in Pharmacology, 2014 71:147-163. [cited by applicant]
Qiao et al., “Role of proBDNF and BDNF in dendritic spine plasticity and depressive-like behaviors induced by an animal model of depression,” Brain Research, 2017, 1663:29-37. [cited by applicant]
Quesseveur et al., “BDNF overexpression in mouse hippocampal astrocytes promotes local neurogenesis and elicits anxiolytic-like activities,” Translational Psychiatry, 2013, 3(e253), 13 pages. [cited by applicant]
Rahimiane tal., “HIV-1 Tat-shortened neurite outgrowth through regulation of microRNA-132 and its target gene expression,” Journal of Neuroinflammation, Sep. 2016, 13(247), 17 pages. [cited by applicant]
Ramirez et al., “Neurotrophins prevent HIV Tat-induced neuronal apoptosis via a nuclear factor-kappaB (NF-kappaB)-dependent mechanism,” Journal of Neurochemistry, 2001, 78:874-889. [cited by applicant]
Rossi et al., “Brain-derived neurotrophic factor (BDNF) is required for the enhancement of hippocampal neurogenesis following environmental enrichment,” The European Journal of Neuroscience, 2006, 24, 1850-1856. [cited by applicant]
Sakane et al., “Carboxyl-directed pegylation of brain-derived neurotrophic factor markedly reduces systemic clearance with minimal loss of biologic activity,” Pharmaceutical research, 1997, 14:1085-1091. [cited by applicant]
Schmid et al., “A domain of clathrin that forms coats,.” PNAS USA, Jan. 1982, 79:91-95. [cited by applicant]
Schmitt et al., “Detection of behavioral alterations and learning deficits in mice lacking synaptophysin,” Neuroscience, 2009, 162:234-243. [cited by applicant]
Shin et al., “Human immunodeficiency virus-1 protein Tat induces excitotoxic loss of presynaptic terminals in hippocampal cultures,” Molecular and cellular neurosciences, 2013, 54, 22-29. [cited by applicant]
Sirianni et al., “The behavioral and biochemical effects of BDNF containing polymers implanted in the hippocampus of rats,” Brain Research, Mar. 2010, 1321:40-50. [cited by applicant]
Snyder et al., “Adult-born hippocampal neurons are more numerous, faster maturing, and more involved in behavior in rats than in mice,” The Journal of Neuroscience, Nov. 2009, 29(46):14484-14495. [cited by applicant]
Soderquist et al., “PEGylation of brain-derived neurotrophic factor for preserved biological activity and enhanced spinal cord distribution,” Journal of Biomedical Materials Research., Dec. 2009, Part A 91, 719-729. [cited by applicant]
Song et al., “BDNF at the synapse: why location matters,” Molecular Psychiatry, Oct. 2017, 22(10):1370-1375. [cited by applicant]
Teng, et al., “ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and sortilin,” The Journal of Neuroscience, Jun. 2005, 25(22):5455-5463. [cited by applicant]
Vaka et al., “Delivery of brain-derived neurotrophic factor via nose-to-brain pathway,” Pharm Res, Feb. 2012, 29(2):441-447. [cited by applicant]
Vitaliano et al., “Clathrin nanoparticles efficiently deliver BDNF to mouse hippocampus and enhance neurogensis, synaptogenesis and cognition in HIV/neuroAIDS mouse model,” Commun. Biol., Mar. 2022, 5(1), 17 pages. [cited by applicant]
Wiley et al., “Distribution of brain HIV load in AIDS,” Brain Pathology, 1998, 8:277-284. [cited by applicant]
Wojtowicz et al., “BrdU assay for neurogenesis in rodents,” Nature Protocols, 2006 1(3):1399-1405. [cited by applicant]
Woo et al., “Activation of p75NTR by proBDNF facilitates hippocampal long-term depression,” Nature Neuroscience, Aug. 2005, 8(8):1069-1077. [cited by applicant]
Yang et al., “proBDNF negatively regulates neuronal remodeling, synaptic transmission, and synaptic plasticity in hippocampus,” Cell reports, May 2014, 7(3):796-806. [cited by applicant]
Yasuda et al., “Robust stimulation of TrkB induces delayed increases in BDNF and Arc mRNA expressions in cultured rat cortical neurons via distinct mechanisms,” Journal of Neurochemistry, 2007, 103:626-636. [cited by applicant]
Zhang et al., “Blood-brain barrier targeting of BDNF improves motor function in rats with middle cerebral artery occlusion,” Brain Research, Aug. 2006, 1111:227-229. [cited by applicant]
Zhang et al., “Brain-derived neurotrophic factor ameliorates learning deficits in a rat model of Alzheimer's disease induced by abeta1-42,” PLoS One, Apr. 2015, 10, e0122415, 14 pages. [cited by applicant]
Zheng et al., “The basal level of intracellular calcium gates the activation of phosphoinositide 3-kinase-Akt signaling by brain-derived neurotrophic factor in cortical neurons,” Journal of Neurochemistry, 2008, 106:125… [cited by applicant]
Zhu et al., “Intranasal administration: a potential solution for BBB delivering neurotrophic factors,” Histology and Histopathology, 2012, 27:537-548. [cited by applicant]
Akaike et al., “Selected papers of Hirotugu Akaike,” Perspectives in Statistics (Kitagawa ed.), Jan. 1998, 432 pages. [cited by applicant]
Alcala-Barraza et al., “Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS,” Journal of Drug Targeting, Apr. 2010, 18(3):179-190. [cited by applicant]
Angelov et al., “Multicompartment lipid cubic nanoparticles with high protein upload: millisecond dynamics of formation,” ACS Nano, May 2014, 8(5):5216-5226. [cited by applicant]
Brodsky, “Diversity of clathrin function: new tricks for an old protein.,” Annu. Rev. Cell Dev. Biol., Jul. 2012, 28:309-336. [cited by applicant]
Butler et al., “Neurodegenerative effects of recombinant HIV-1 Tat(1-86) are associated with inhibition of microtubule formation and oxidative stress-related reductions in microtubule-associated protein-2(a,b),” Neuroch… [cited by applicant]
Carey et al., “Conditional Tat protein expression in the GT-tg bigenic mouse brain induces gray matter density reductions,” Progress in Neuro-Psychopharmacology & Biological Psychiatry, Jun. 2012, 43:49-54. [cited by applicant]
Carey et al., “Expression of HIV-Tat protein is associated with learning and memory deficits in the mouse,” Behavioural Brain Research, Apr. 2012, 229(1):48-56. [cited by applicant]
Coffey et al., “Brain derived neurotrophic factor induces a rapid upregulation of synaptophysin and tau proteins via the neurotrophin receptor TrkB in rat cerebellar granule cells,” Neuroscience Letters, May 1997, 227(3… [cited by applicant]
Couillard-Despres et al., “Doublecortin expression levels in adult brain reflect neurogenesis,” The European Journal of Neuroscience, Jan. 2005, 21,(1):1-14. [cited by applicant]
Fitting et al., “Synaptic dysfunction in the hippocampus accompanies learning and memory deficits in human immunodeficiency virus type-1 Tat transgenic mice,” Biological Psychiatry, Mar. 2012, 73(5):443-453. [cited by applicant]
Fukumitsu et al., “BDNF and NT-3 modulate expression and threonine phosphorylation of microtubule-associated protein 2 analogues, and alter their distribution in the developing rat cerebral cortex,” Neuroscience Letters… [cited by applicant]
Ghosh et al., “Requirement for BDNF in activity-dependent survival of cortical neurons,” Science, Mar. 1994, 263(5153):1618-1623. [cited by applicant]
Guo et al., “Differential effects of transient and sustained activation of BDNF-TrkB signaling,” Developmental Neurobiology, Mar. 2018, 78(7):647-659. [cited by applicant]
Hill et al., “Chronic Intrahippocampal Infusion of HIV-1 Neurotoxic Proteins: A Novel Mouse Model of HIV-1 Associated Inflammation and Neural Stem Cell Dysfunction,” Journal of Neuroimmune Pharmacology, Mar. 2019, 14:37… [cited by applicant]
Jiang et al., “Nanoformulation of Brain-Derived Neurotrophic Factor with Target Receptor-Triggered-Release in the Central Nervous System,” Advanced Functional Materials, Dec. 2017, 28(6), 11 pages. [cited by applicant]
Kang et al., “Long-lasting neurotrophin-nduced enhancement of synaptic transmission in the adult hippocampus,” Science, Mar. 1995, 267(5204):1658-1662. [cited by applicant]
King et al., “HIV tat and neurotoxicity,” Microbes and infection, Apr. 2006, 8(5):1347-1357. [cited by applicant]
Knaus et al., “Expression of synaptophysin during postnatal development of the mouse brain,” Journal of Neurochemistry, Oct. 1986, 47(4):1302-1304. [cited by applicant]
Kummer, “Tritium radiolabeling of antibodies to high specific activity with N-succinimidyl [2,3-3H]propionate: use in detecting and analyzing monoclonal antibodies,” Methods in Enzymology, 1986, 121, 670-678. [cited by applicant]
Langford et al., “Doxycycline-inducible and astrocyte-specific HIV-1 Tat transgenic mice (iTat) as an HIV/neuroAIDS model,” Journal of Neurovirology, Nov. 2017, 24(2):168, 26 pages. [cited by applicant]
Leal et al., “Regulation of hippocampal synaptic plasticity by BDNF,” Brain Research, Sep. 2015, 1621(24):82-101. [cited by applicant]
Lebel et al., “Use of a rodent neurotoxicity screening battery in the preclinical safety assessment of recombinant-methionyl human brain-derived neurotrophic factor,” Neurotoxicology, Sep. 1, 1996, 17(3-4):851, 14 pages. [cited by applicant]
Levine et al., “Multilevel analysis of neuropathogenesis of neurocognitive impairment in HIV,” Journal of Neurovirology, Dec. 2015, 22(4):431-441. [cited by applicant]
Lian et al., “Exogenous BDNF increases neurogenesis in the hippocampus in experimental [cited by applicant]
Lindholm et al., “Autocrine-paracrine regulation of hippocampal neuron survival by IGF-1 and the neurotrophins BDNF, NT-3 and NT-4,” The European Journal of Neuroscience, Jul. 1996, 8(7):1452-1460. [cited by applicant]
Liu et al., “7, 8-dihydroxyflavone, a small molecular TrkB agonist, is useful for treating various BDNF-implicated human disorders, ” Translational Neurodegeneration, 2016, 5(2). [cited by applicant]
Marks et al., “HIV-1 Tat causes cognitive deficits and selective loss of parvalbumin, somatostatin, and neuronal nitric oxide synthase expressing hippocampal CA1 interneuron subpopulations,” Journal of Neurovirology, Ma… [cited by applicant]
McLaughlin et al., “Conditional Human Immunodeficiency Virus Transactivator of Transcription Protein Expression Induces Depression-like Effects and Oxidative Stress,” Biological Psychiatry: Cognitive Neuroscience and Ne… [cited by applicant]
Meeker et al., “Protein changes in CSF of HIV-infected patients: evidence for loss of neuroprotection,” Journal of Neurovirology, May 2011, 17(3):258, 30 pages. [cited by applicant]
Nagahara et al., “Potential therapeutic uses of BDNF in neurological and psychiatric disorders,” Nature reviews. Drug discovery 10, 209-219 (2011). [cited by applicant]
Poduslo et al., “Permeability at the blood-brain and blood-nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF,” Molecular Brain Research, 1996 36, 280-286. [cited by applicant]
Scharfman et al., “Increased neurogenesis and the ectopic granule cells after intrahippocampal BDNF infusion in adult rats,” Experimental Neurology, 2005, 192:348-356. [cited by applicant]
Scholzen et al., “The Ki-67 protein: from the known and the unknown,” Journal of Cellular Physiology, Jan. 2000, 182:311-322. [cited by applicant]
Yamada et al., “Role for brain-derived neurotrophic factor in learning and memory,” Life Sciences, Jan. 4, 2002, 70(7):735-44. [cited by applicant]
Yan et al., “Expression of brain-derived neurotrophic factor protein in the adult rat central nervous system,” Neuroscience, Mar. 10, 1997, 78(2):431-48. [cited by applicant]
Yang et al., “BDNF promotes the growth of human neurons through crosstalk with the Wnt/beta-catenin signaling pathway via GSK-3beta,” Neuropeptides, Dec. 2015, 54:35-46. [cited by applicant]
Zagrebelsky et al., “Form follows function: BDNF and its involvement in sculpting the function and structure of synapses,” Neuropharmacology, Jan. 1, 2014, 76:628-38. [cited by applicant]
Zhang et al., “Neural stem cell transplants improve cognitive function without altering amyloid pathology in an APP/PS1 double transgenic model of Alzheimer's disease,” Molecular Neurobiology, Oct. 2014, 50:423-37. [cited by applicant]
Aime et al., “Lanthanide(iii) chelates for NMR biomedical applications,” Chemical Society Reviews, 1998, 27:19-29. [cited by applicant]
Anitua et al., “Delivering growth factors for therapeutics,” Trends in Pharmacological Sciences, 2007, 29(1):37-41. [cited by applicant]
Augustine et al., “Clathrin and synaptic vesicle endocytosis: studies at the squid giant synapse,” Biochemical Society Transactions, 2006, 34, (part 1):68-72. [cited by applicant]
Barrientos et al., “Growth factors and cytokines in wound healing,” Wound Repair and Regeneration, 2008, 16(5):585-601. [cited by applicant]
Battistelli, et al. Ultra-bright and stimuli-responsive fluorescent nanoparticles for bioimaging, WIREs Nanomed Nanobiotechnol, 2016, 8:139-150. [cited by applicant]
Beduneau et al., “Active targeting of brain tumors using nanocarriers,” Biomaterials, 2007, 28(33):4947-4967. [cited by applicant]
Begley et al., “Delivery of therapeutic agents to the central nervous system: the problems and the possibilities,” Pharmacology & Therapeutics, 2004, 104:29-45. [cited by applicant]
Bethune et al., “Coatomer, the Coat Protein of COPI Transport Vesicles, Discriminates Endoplasmic Reticulum Residents from p24 Proteins,” Mol. Cell. Biol., Nov. 2006, 26(21):8011-8021. [cited by applicant]
Bifrare et al., “Brain-Derived Neurotrophic Factor Protects against Multiple Forms of Brain Injury in Bacterial Meningitis,” The Journal of Infectious Diseases, 2005, 191(1):40-5. [cited by applicant]
Boado et al., “RNA Interference and Nonviral Targeted Gene Therapy of Experimental Brain Cancer,” The American Society for Experimental Neuro Therapeutics, Inc., 2005, 2:139-150. [cited by applicant]
Brodsky et al., “Biological basket weaving: formation and function of clathrin-coated vesicles,” Annu. Rev. Cell Dev. Biol., 2001, 17:517-568. [cited by applicant]
Brodsky et al., Clathrin's Achilles' ankle, Nature, Dec. 2004, 432:568-569. [cited by applicant]
Campbell et al., “Identification of a Protein Kinase as an IntrinsicComponent of Rat Liver Coated Vesicles,” Biochemistry, 1984, 23:4420-4426. [cited by applicant]
Carbonaro et al., High efficient fluorescent stable colloidal sealed dye-doped mesostructured silica nanoparticles, Microporous and Mesoporous Materials, 2016, 225:432-439. [cited by applicant]
Cotten et al., “Receptor-Mediated Transport of DNA into Eukaryotic Cells,” Methods Enzym, 1993, 217:618-644. [cited by applicant]
Crosetto et al., “Oncogenic breakdowns in endocytic adaptor proteins,” FEBS Letters, 2005, 579:3231-3238. [cited by applicant]
Crowther et al., “Assembly and Packing of Clathrin Into Coats,” The Journal of Cell Biology, 1981, 91:790-797. [cited by applicant]
Datta et al., “High Relaxivity Gadolinium Hydroxypyridonate-Viral Capsid Conjugates: Nanosized MRI Contrast Agents,” J Am. Chem. Soc., 2008, 130:2546-2552. [cited by applicant]
Davidson et al., “Molecular medicine for the brain: silencing of disease genes with RNA interference,” Lancet Neurology, Mar. 2004, 3:145-149. [cited by applicant]
De Boer et al., “Drug Targeting to the Brain,” Annu. Rev. Pharmacol. Toxicol., 2007, 47:323-355. [cited by applicant]
Denardo et al., “Effect of Molecular Size of Pegylated Peptide on the Pharmacokinetics and Tumor Targeting in Lymphoma-Bearing Mice,” Clinical Cancer Research, Sep. 1, 2003, 9:3854S-3864S. [cited by applicant]
Dhuria et al., “Novel vasoconstrictor formulation to enhance intranasal targeting of neuropeptide therapeutics to the central nervous system,” The Journal of Pharmacology, 2008, 328(1):312-320. [cited by applicant]
Edeling et al., “Life of a clathrin coat: insights from clathrin and AP structures,” Nature Reviews, Molecular Cell Biology, Jan. 2006, 7:32-44. [cited by applicant]
Ehrlich et al., “Endocytosis by Random Initiation and Stabilization of Clathrin-Coated Pits,” Cell, Sep. 3, 2004, 118:591-605. [cited by applicant]
Enari et al., “Requirement of clathrin heavy chain for p53-mediated transcription,” Genes & Development, 2006, 20:1087-1099. [cited by applicant]
ExQor Quad Chard, RFI Response to President's Council on Science & Technology meeting, PCAST/The White House, Jun. 22, 2010, Poster, 1 page. [cited by applicant]
ExQor Technologies, Inc. “A 21st Century Pharma Platform for CNS Drugs & Cognitive Sensors,” presentation, 2016, Vialiano, et al, 10 pages. [cited by applicant]
ExQor Technologies, Inc. TruStudy, “A Unified Drug Development & Cognitive Analysis Platform,” presentation, 2015, Vitaliano, et al., 6 pages. [cited by applicant]
ExQor Technologies, Inc., ExQor DuoThera, Feb. 2015, Presentation to Royal College of Surgeons In Ireland, Dublin, Ireland, 14 pages. [cited by applicant]
Fda.gov[online] “Route of Administration,” Nov. 2017, [retrieved on Aug. 12, 2019], retrieved from URL<www.fda.gov/drugs/data-standards-manual-monographs/route-administration>, 5 pages. [cited by applicant]
Ferguson et al., “Conformation of a clathrin triskelion in solution,” Biochemistry, 2006, 45(18):5916-22. [cited by applicant]
Fotin et al., “Molecular model for a complete Clathrin lattice from electron cryomicroscopy,” Nature, 2004, 432:573-579. [cited by applicant]
Fotin et al., “Structure of an auxilin-bound clathrin coat and its implications for the mechanism of uncoating,” Nature, 2004, 432:649-653. [cited by applicant]
Futatsumori, Identification and characterization of novel isoforms of COP 1 subunits. J. Biochem., 2000 128:793-801. [cited by applicant]
Graff et al., Nasal Drug Administration: Potential for Targeted Central Nervous System Delivery, Journal of Pharmaceutical Sciences, Jun. 2005, 94(6):1187-1195. [cited by applicant]
Gragera et al., “Molecular and ultrastructural basis of the blood-brain barrier function. Immunohistochemical demonstration of Na+/K+ ATPase, alpha-actin, phosphocreatine and clathrin in the capillary wall and its micro… [cited by applicant]
Granseth et al., “Clathrin-mediated endocytosis: the physiological mechanism of vesicle retrieval at hippocampal synapses,” J Physiol., 2007 585.3:681-686. [cited by applicant]
Granseth et al., “The role of endocytosis in regulating the strength of hippocampal synapses,” J Physiol, 2008, 586.24:5969-5982. [cited by applicant]
Greene et al., “Complete reconstitution of clathrin basket formation with recombinant protein fragments: adaptor control of clathrin self-assembly,” Traffic, Jan. 2000, 1(1):69-75. [cited by applicant]
Gurkan et al., “The COPII cage: unifying principles of vesicle coat assembly,” Nature Reviews, Molecular Cell Biology, 2006, 7:727-738. [cited by applicant]
Haar et al., “Atomic Structure of Clathrin: A b Propeller Terminal Domain Joins a Zigzag Linker,” Cell, 1998, 95:563-573. [cited by applicant]
Hanczyc, et al., “Multiphoton absorption in amyloid protein fibres,” Nature Photonics, Nov. 3, 2013, 7:969-972. [cited by applicant]
Heerssen et al., “Clathrin Dependence of Synaptic-Vesicle Formation at the [cited by applicant]
Heuser et al., “Evidence for recycling of synaptic vesicle membrane during transmitter release at the frog neuromuscular junctio, ” The Journal of Cell Biology, 1973, 57(2):315-44. [cited by applicant]
Higgins et al., “Snap-shots of clathrin-mediated endocytosis,” Trends in Biochemical Sciences, May 2002, 27(5):257-263. [cited by applicant]
Hooker et al., “Magnetic Resonance Contrast Agents from Viral Capsid Shells: A Comparison of Exterior nd Interior Cargo Strategies,” Nano Lett., 2007, 7(8):2207-2210. [cited by applicant]
Huang et al., “Analysis of clathrin-mediated endocytosis of EGF receptor by RNA interference,” JBC Papers in Press, Published on Feb. 25, 2004 as Manuscript C400046200. [cited by applicant]
Illum et al., “Nanoparticulate Systems for Nasal Delivery of Drugs: A Real Improvement over Simple Systems?” Journal of Pharmaceutical Sciences, Mar. 2007, 96(3). [cited by applicant]
Illum et al., “Nasal drug delivery: new developments and strategies,” Dec. 2002, DDT, 7(23):1184-1189. [cited by applicant]
Ivanov et al., “Exocytosis and Endocytosis,” Human Press, 2008, Book, ISBN: 1588298655, 9781588298652, 16 pages. [cited by applicant]
Jacob et al., “Quantum Plasmonics,” MRS Bulletin, Aug. 2012, 37(8):761-767. [cited by applicant]
Kabanov et al., “New Technologies for Drug Delivery Across the Blood Brain Barrier,” Current Pharmaceutical Design, 2004, 10(12):1355-01363. [cited by applicant]
Karu et al., “Multiple Roles of Cytochrome c Oxidase in Mammalian Cells Under Action of Red and IR-A Radiation,” IUBMB Life, Jul. 28, 2010, 62(8): 607-610. [cited by applicant]
Kasprowicz et al., “Inactivation of Clathrin heavry chain inhibits synaptic recycling but allows bulk membrane uptake,” J. Cell Biol. vol. 182 Nov. 5 1007-1016. [cited by applicant]
Kedersha et al., “Isolation and Characterization of a Novel Ribonucleoprotein ParticelL Large Structures contain a Single Species of Small RNA,” J. Cell Biology, 1986, 103:699-709. [cited by applicant]
Keen et al., “Clathrin Assembly Proteins: Affinity Purification and a Model for Coat Assembly,” The Journal of cell Biology, Nov. 1987, 105:1989-1998. [cited by applicant]
Keen et al., “Clathrin-coated vesicles: isolation, dissociation and factor-dependent reassociation of clathrin baskets,” Cell, Feb. 1979, 16(2):303-312, 10 pages. [cited by applicant]
Kim et al., “Targeted Noninvasive Delivery of Novel Clathrin-based Superparamagnetic Iron Oxide Nanoparticles for Magnetic Resonance Imaging of Dopamine Transporters in Mouse Brain.” Society of Neuroscience, Nov. 3-7, 2… [cited by applicant]
Kim et al., “Clathrin Nanoparticles Efficiently Deliver BDNF to the Hippocampus, Enhance Neurogenesis, and Learning and Memory in a Mouse Model of HIV,” Society of Neuroscience, Nov. 11-15, 2017, Washington, DC, 2 pages… [cited by applicant]
Kirchhausen et al. “Protein organization in clathrin trimers,” Cell, Mar. 1981, 23(3):755-761, 7 pages. [cited by applicant]
Kirchhausen et al., “Configuration of clathrin trimers: evidence from electron microscopy,” Ultrastruct Mal Struct Res, 1986, 94(3):199-208. [cited by applicant]
Kirchhausen et al., “Clathrin heavy chain: molecular cloning and complete primary structure,” PNAS, Dec. 1, 1987, 84:24 8805-8809. [cited by applicant]
Kirchhausen et al., “Clathrin,” Annu. Rev. Biochem., 2000, 69:699-727. [cited by applicant]
Kocsis et al., “Image averaging of flexible fibrous macromolecules: the clathrin triskelion has an elastic proximal segment,” J Struct Biol, 1991, 107(1):6-14. [cited by applicant]
Kotova et al., “AFM visualization of clathrin triskelia under fluid and in air,” FEBS Lett., 2010, 584(1):44-48. [cited by applicant]
Liske, Holly, et al. “Optical control of neuronal excitation and inhibition using a single opsin protein, ChR2.” Scientific Reports. Oct. 31, 2013, 3(1):1-7. [cited by applicant]
Liu et al., “Regulation of Clathrin Assembly and Trimerization, Defined Using Recombinant Triskelion Hubs,” Cell, Oct. 20, 1995, 83:257-267. [cited by applicant]
Lowe et al., “In Vivo Assembly of Coatomer, the COP-I Coat Precursor,” The Journal of Biological Chemistry, 996, 271(48):30725-30730. [cited by applicant]
Ma et al., “Intranasally delivered TGF-B1 enters brain and regulates gene expressions of its receptors in rats,” Brain Research Bulletin, 2007, 74:271-277. [cited by applicant]
Mainardes et al., “Liposomes and Micro/Nanoparticles as Colloidal Carriers for Nasal Drug Delivery,” Current Drug Delivery, 2006, 3:275-285. [cited by applicant]
McMahon et al., “COP and clathrin-coated vesicle budding: different pathways, common approaches,” Current Opinion in Cell Biology, 2004, 16:379-391. [cited by applicant]
Morille et al., “Progress in developing cationic vectors for non-viral systemic gene therapy against cancer,” Biomaterials, 2008, 29:3477-3496. [cited by applicant]
Morrow, “Cadmium and Cadmium Alloys,” Kirk-Othmer Encyclopedia of Chemical Technology, Mar. 12, 2010, 36 pages. [cited by applicant]
Mulder et al., “Quantum Dots with a Paramagnetic Coating as a Bimodal Molecular Imaging Probe,” Nano Lett. 2006, 6(1):1-6. [cited by applicant]
Mural et al., A comparison of whole-genome shotgun-derived mouse chromosome 16 and the human genome. Science 296:1661-1671(2002). [cited by applicant]
Nathke et al., “Folding and Trimerization of Clathrin Subunits at the Triskelion Hub,” Cell, Mar. 6, 1992, 66:899-910. [cited by applicant]
Nathke et al., “The Calcium-Binding Site of Clathrin Light Chains,” The Journal of Biological Chemistry, Oct. 25, 1990, 265(30):18621-18627. [cited by applicant]
Ohno et al., “Clathrin-associated adaptor protein complexes,” Journal of Cell Science, 2006, 119(18):3719-3721. [cited by applicant]
Parham et al., “The Occurrence of Disulphide Bonds in Purified Clathrin Light Chains,” Biochem. J., 1989, 257:775-781. [cited by applicant]
Pearse et al., “Purification and properties of 100-kd proteins from coated vesicles and their reconstitution with clathrin,” EMBO J. 1984, 3(9):1951-1957. [cited by applicant]
Podgorski et al., “Ultra-Bright and -Stable Red and Near-Infrared Squaraine Fluorophores for In Vivo Two-Photon Imaging,” Dec. 14, 2012, 7(12):PloS One, 7 pages. [cited by applicant]
Qualmann et al., “Molecular links between endocytosis and the actin cytoskeleton,” The Journal of cell biology, 2000, 150(5):F111-6, 6 pages. [cited by applicant]
Rahimzadeh et al., “Cadmium toxicity and treatement: An Update,” Caspian J Intern Med, Apr. 2017, 8(3):135-45. [cited by applicant]
Rapoport et al., “A motif in the clathrin heavy chain required for the Hsc70/auxilin uncoating reaction,” Molecular Biology of the Cell, Jan. 2008, 19(1):405-413. [cited by applicant]
Rautio et al., “Drug Devlivery Ststems for Brain Tumor Therapy,” Current Pharmaceutical Design, 2004, 10:1341-1353. [cited by applicant]
Reddy et al., “Vascular Targeted nanoparticles for Imaging and Treatment of Brain Tumores,” Clin Cancer Res, 2006, 12(22):6677-6686. [cited by applicant]
Redlingshöfer et al., “Clathrin light chain diversity regulates membrane deformation in vitro and synaptic vesicle formation in vivo,” Proceedings of the National Academy of Sciences, Sep. 22, 2020, 117(38):23527-38. [cited by applicant]
Ringstad et al., “Endophilin/SH3p4 is required for the transition from early to late stages in clathrin-mediated synaptic vesicle endocytosis,” Neuron, 1999, 24(1):143-54. [cited by applicant]
Rodal et al., “Synaptic Endocytosis: Illuminating the Role of Clathrin Assembly,” Current Biology, 2008, 8(6):R259-R261. [cited by applicant]
Royle, “The cellular functions of clathrin,” Cell Mol. Life Sci., Aug. 2006, 63(16):1823-1832. [cited by applicant]
Sadasivan et al., “Novel protein-inorganic nanoparticles prepared by inorganic replication of self-assembled clathrin cages and triskelia,” Soft Matter, 2008, 4, 2054-58, 5 pages. [cited by applicant]
Seppen et al., “Interation of Clathrin with Large Unilamellar Phospholipid Vesicles at Neutral pH. Lipid Dependence and Protein Penetration,” Biochimica et Biophysica Acta, 1992, 1106:209-215. [cited by applicant]
Sheff et al., “Biochemical Heterogeneity and Phosphorylation of Coatomer Subunits,” The Journal of Biological Chemistry, 1996, 271(12):7230-7236. [cited by applicant]
Smith et al., “Clathrin coats at 21 Angstrom resolution: a cellular assembly designed to recycle multiple membrane receptors,” The EMBO Journal, Sep. 1, 1998, 17(17):4943-4953. [cited by applicant]
Spang et al., “Coatomer, Arf1p, and nucleotide are required to bud coat protein complex I-coated vesicles from large synthetic liposomes,” Proc. Natl. Acad. Sci. USA., 1998, 95(19):11199-11204. [cited by applicant]
Teng et al., “Clathrin-mediated endocytosis near active zones in snake motor boutons,” Journal of Neuroscience, 2000, 20(21):7986-93. [cited by applicant]
Thorne et al., “Quantitative analysis of the olfactory pathway for drug delivery to the brain,” Brain Research, 1995, 692:278-282. [cited by applicant]
Troutman et al., “Biodegradable plasmon resonant nanoshells,” Advanced Materials, Jul. 2, 2008, 20(13):2604-8. [cited by applicant]
Turker et al., “Nasal route and drug delivery systems,” Pharm Wold Sci, 2004, 26:137-142. [cited by applicant]
Ungewickell et al., “Clathrin: A good view of a shapely leg,” Current Biology, 1999, 9:R32-R35. [cited by applicant]
Vieira et al., “Control of EGF Receptor Signaling by Clathrin-Mediated Endocytosis,” Science, Dec. 20, 1996, vol. 274. [cited by applicant]
Vigh et al., “Nonvisual photoreceptors of the deep brain, pineal organs and retina,” Histology and Histopathology, 2002, 17:555-590. [cited by applicant]
Vinck et al., “Increased fibroblast proliferation induced by light emitting diode and low power laser irradiation,” Lasers Med Sci (2003) 18(2):95-99. [cited by applicant]
Virshup et al., “Clathrin-coated Vesicle Assembly Polypeptides: Physical Properties and Reconstitution Studies with Brain Membranes,” The Journal of Cell Biology, 1988, 106:39-50. [cited by applicant]
Vitaliano et al., “New Clathrin-Based Nanotechnology for Delivering Antibodies to the Brain,” Neuroscience 2012, New Orleans, 1 page. [cited by applicant]
Vitaliano et al., Presentation, “Dopamine Transporter Nanporobes for CNS Molecular Magnetic Resonance Imaging and Targeted drug Delivery,” 2012, Presented at the World Molecular Imaging Conference (WMIC), 2 pages. [cited by applicant]
Vitaliano et al., “A Novel Neurotheranostic for Magnetic Resonance Imaging of Dopamine Transporters and Treatment of Dopaminergic Neurodegeneration,” 74th Annual Meeting of the Society of Biological Psychiatry (SOBP), C… [cited by applicant]
Vitaliano et al., “Bioengineered Clathrin MRI Nanoprobes for Molecular Imaging of Dopamine Receptors,” Presentation, American College of Neuropsychopharmacology (ACNP) 2010, 36 pages. [cited by applicant]
Vitaliano et al., “Clathrin MRI Nanoprobes for Molecular Imaging of Dopamine Receptors,” 49th Meeting of American College of Neuropsycho-Pharmacology, Oral Presentation, Miami, FL, 2010, 36 pages. [cited by applicant]
Vitaliano et al., “Clathrin Nanoparticles Efficiently Deliver Antibodies to Targeted Dopamine Brain Regions,” 54th Meeting of American College of Neuopsychopharmacology, 2015, Hollywood FL, 1 page. [cited by applicant]
Vitaliano et al., “Clathrin Nanoparticles Efficiently Deliver BDNF to the Hippocampus, Enhance Neurogenesis and Learning and Memory in a Mouse Model of HIV,” 56th Meeting of American College of Neuropsychopharmacology, … [cited by applicant]
Vitaliano et al., “Clathrin Nanoparticles Efficiently Deliver BDNF to the Hippocampus, Reverse BDNF Deficits and Improve Cell Survival and Proliferation in a Gt-Tg Mouse Model of HIV,” 55th Meeting of American College o… [cited by applicant]
Vitaliano et al., “Clathrin Nanoparticles Efficiently Deliver BDNF to the Hippocampus, Reverse BDNF Deficits and Improve Cell Survival and Proliferation in a GT-tg Mouse Model, ” 72nd Annual Meeting of the Society of Bi… [cited by applicant]
Vitaliano et al., “Clathrin Nanoparticles Efficiently Deliver BDNF to the Hippocampus, Reverse Oxidative Stress, Enhance Synaptogenesis and Memory in Alzheimer's Mouse Model,” Neuroscience, Poster, Chicago, IL, Oct. 19-… [cited by applicant]
Vitaliano et al., “Clathrin Nanoparticles Efficiently Deliver Brain-Derived Neurotrophic Factor (BDNF) to the Hippocampus, Reverse Oxidative Stress and Enhance Synaptogenesis and Memory in Alzheimer's Mouse Model,” 75th… [cited by applicant]
Vitaliano et al., “Clathrin Triskelia as Potential High-Relaxivity Magnetic Resonance Nanoprobes for Molecular Imaging of Dopamine Receptors,” 2010 ACNP Annual Meeting, Panel, Session No. 274, Dec. 9, 2010, 1 page. [cited by applicant]
Vitaliano et al., “Clathrin Triskelia as Potential High-Relaxivity Magnetic Resonance Nanoprobes for Molecular Imaging of Dopamine Receptors,” WMIC (World Molecular Imaging Congress) 2011, Presentation No. P040 Poster S… [cited by applicant]
Vitaliano et al., “High-relaxivity magnetic resonance clathrin-based nanoprobes for molecular imaging of dopamine receptors,” Neuroscience Annual Meeting, 2011, Program#/Poster#: 619.21YY13 Washington DC, 2 pages. [cited by applicant]
Vitaliano et al., “Neurotheranostic for Magnetic Resonance Imaging of Dopamine Transporters and Treatment of Dopaminergic Neurodegeneration,” Society of Neuroscience, Virtual Event Session: (P383), Jan. 11, 2021, 1 page. [cited by applicant]
Vitaliano et al., “Neurotheranostic for MRI of Dopamine Transporters (DAT) and Treatment of Dopaminergic Neurodegeneration,” Contrast Media Research (CMR) Symposium, Erice, Italy, Oral Presentation, Nov. 10-15, 2019, 18… [cited by applicant]
Vitaliano et al., “New Clathrin Nanoparticles Efficiently Deliver Antibodies to Targeted Dopamine Brain Region,” 71st Annual Meeting of the Society of Biological Psychiatry (SOBP), Oral Presentation, Atlanta, GA, USA, 2… [cited by applicant]
Vitaliano et al., “New Clathrin Nanoparticles Efficiently Deliver D3 Antibodies to Targeted Dopamine Brain Regions,” College on Problems of Drug Dependence (CPDD) Conference, Oral Presentation, San Diego, Jun. 2018, 19 … [cited by applicant]
Vitaliano et al., “New Clathrin Nanotechnology for Delivering Antibodies to the Brain,” Oral Presentation given at Society of Biological Psychiatry's 68th annual meeting, San Francisco, CA, May 16-18, 2013, 12 pages. [cited by applicant]
Vitaliano et al., “New Clathrin-Based Nanoplatforms for Magnetic Resonance Imaging,” PloS One, May 2012, 7(5):e35821, 14 pages. [cited by applicant]
Vitaliano et al., “New Dopamine Transporter Nanoprobes for CNS Molecular Magnetic Resonance Imaging and Targeted Drug Delivery,” Society of Biological Psychiatry, 70th Annual Convention, Toronto, Canada, 2015, 1 page. [cited by applicant]
Vitaliano et al., “New Nanoprobes for Magnetic Resonance Imaging of Dopamine Transporters,” Oral Presentation, World Molecular Imaging Congress, Savannah, Georgia, 2013. [cited by applicant]
Vitaliano et al., “New Quantum Bio-Nanotechnologies for MRI Therapeutics in the CNS,” Proc. QIM, Knowledge Federation Dialog, in press, presented in Belgrade Serbia, 2018, 21 pages. [cited by applicant]
Vitaliano et al., “Novel Antibody-Targeted Clathrin-Based Superparamagnetic Iron Oxide Nanoprobes for MR Imaging of Dopamine Transporters,” WMIC, Virtual, Oct. 7-9, 2020, 15 pages. [cited by applicant]
Vitaliano et al., “Novel Clathrin-Based Superparamagnetic Iron Oxide Nanoparticles for Magnetic Resonance Imaging of Dopamine Transporters,” 73rd Annual Meeting of the Society of Biological Psychiatry (SOBP), May 10-12,… [cited by applicant]
Vitaliano et al., “Targeting Activated Microglia in the Brain by Delivering Antibodies via Nanoparticles,” 53rd Meeting of American College of Neuropsychopharmacology, Phoenix, AZ, 2014,1 page. [cited by applicant]
Vitaliano et al., “Targeting Microglia in the Brain by Delivering Antibodies via Nanoparticles,” Oral Presentation, Society for Neuroscience, Nov. 13, 2013, Annual Meeting, San Diego, CA, 14 pages. [cited by applicant]
Vitaliano et al., Presentation, “Bioengineered Clathrin MRI Nanoprobes for Molecular Imaging of Dopamine Receptors,” Presented at the Proceedings of the Annual 2010 Meeting of the American College of Neuropsychopharmaco… [cited by applicant]
Vitaliano et al., Presentation, “New Clathrin Nanoparticles Efficiently Deliver Antibodies to Targeted Dopamine Brain Region,” May 13, 2016, Annual Meeting of the Society of Biological Psychiatry (SOBP), 18 pages. [cited by applicant]
Vitaliano et al., “Clathrin Nanoparticles as Potential High-Relaxivity Magnetic Resonance Nanoprobes for Molecular Brain Imaging,” Poster, Molecular Imaging Congress, 2009, Montreal, Canada, 1 page. [cited by applicant]
Vitaliano et al., “Detecting Activated Microglia in the Brain by Delivering Antibodies via Nanoparticles,” Society of Biological Psychiatry 69th Annual Convention, New York, NY, 2014, 1 page. [cited by applicant]
Vitaliano, “Harvard Medical School/Harvard School of Dental Medicine Curriculum Vitae,” MIC, McLean Hospital, 2020, 30 pages. [cited by applicant]
Wakeham et al., Clarthrin self-assembly involves coordinated weak interactions favorable for cellular regulation, EMBO J. 2003, 22(19):4980-4990. [cited by applicant]
Waters et al., “Coatomer': a cytosolic Protein complex containing subunits of non-clathrin-coated Golgi Transport vesicles,” Nature, 1991, 349:248-251. [cited by applicant]
Wilbur et al., “Conformation Switching of Clathrin Light Chain Regulates Clathrin Lattice Assembly,” Developmental Cell, 2010, 18(5):854-861. [cited by applicant]
Wu et al., “Clathrin exchange during clathrin-mediated endocytosis,” The Journal of Cell Biology, Oct. 15, 2001, 155(2):291-300. [cited by applicant]
Wu et al., “Receptor-Mediated Gene Delivery and Expression in Vivo,” J. Biol. Chem., 1988, 263:14621-14624. [cited by applicant]
Ybe et al., “Clathrin self-assembly is regulated by three light-chain residues controlling the formation of critical salt bridges,” the EMBO Journal, 1998, 17(5):1297-1303. [cited by applicant]
Ybe et al., “Contribution of Cysteines to Clathrin Trimerization Domain Stability and Mapping of Light Chain Binding,” Traffic, 2003, 4:850-856. [cited by applicant]
Ybe et al., “Light Chain C-Terminal Region Reinforces the Stability of Clathrin Heavy Chain Trimers,” Traffic, 2007, 8:1101-1110. [cited by applicant]
Yoshimura et al., “Skeletal structure of clathrin triskelion in solution: experimental and theoretical approaches,” Biochemistry, 1991, 30(18):9 4528-4534. [cited by applicant]
Zhang et al., “Clathrin Adaptor GGA1 Polymerizes Clathrin into Tubules,” The Journal of Biological Chemistry, 2007, 282(18):13282-13289. [cited by applicant]
Zhang et al., “Fabrication of novel biomaterials through molecular self-assembly,” Nature Biotechnology, Oct. 2003, 21(10):1171-1178. [cited by applicant]
Zhu et al., “Adaptor Protein 1-Dependent Clathrin Coat Assembly on Synthetic Liposomes and Golgi Membranes,” Methods in Enzymology, 2001, 329(40):379-387. [cited by applicant]
Aron et al., “Location, location: using functional magnetic resonance imaging to pinpoint brain differences relevant to stimulant use,” Addiction, 2007, vol. 102, Suppl. 1, pp. 33-43. [cited by applicant]
Arseniou et al., “HIV infection and depression,” Psychiatry and Clinical Neurosciences, 2014, vol. 68, pp. 96-109. [cited by applicant]
Atwater, Harry A., “The Promise of Plasmonics,” Scientific American, Apr. 2007, vol. 296, pp. 56-63. [cited by applicant]
Baicy et al., “Corticolimbic dysregulation and chronic methamphetamine abuse,” Addiction, 2007, vol. 102, Suppl. 1, pp. 5-15. [cited by applicant]
Bamji et al., “BDNF mobilizes synaptic vesicles and enhances synapse formation by disrupting cadherin-β-catenin interactions,” The Journal of Cell Biology, Jul. 17, 2006, vol. 174, No. 2, pp. 289-299. [cited by applicant]
Barbeau, André, “Dopamine and Disease,” C.M.A. Journal, Oct. 17, 1970, vol. 103, pp. 824-832. [cited by applicant]
Benton, Tami D., “Depression and HIV/AIDS,” Current Psychiatry Reports, 2008, vol. 10, pp. 280-285. [cited by applicant]
Berman et al., “Abuse of Amphetamines and Structural Abnormalities in Brain,” Annals of the New York Academy of Sciences, Oct. 2008, vol. 1141, pp. 195-220. [cited by applicant]
Bhaskar et al., “Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging,” Particle and Fibre Toxicology, 2010, vol. 7, p.… [cited by applicant]
Bhatt et al., “Efficacy and safety of psychostimulants for amphetamine and methamphetamine use disorders: a systematic review and meta-analysis,” Systematic Reviews, 2016, vol. 5, p. 189. [cited by applicant]
Brown et al., “A randomized, double-blind, placebo-controlled trial of citicoline for bipolar and unipolar depression and methamphetamine dependence,” Journal of Affective Disorders, 2012, vol. 143, pp. 257-260. [cited by applicant]
Buchanan et al., “A neurotoxic regimen of methamphetamine exacerbates the febrile and neuroinflammatory response to a subsequent peripheral immune stimulus,” Journal of Neuroinflammation, 2010, vol. 7, p. 82. [cited by applicant]
Cadet et al., “Molecular Bases of Methamphetamine-Induced Neurodegeneration,” International Review of Neurobiology, 2009, vol. 88, pp. 101-119. [cited by applicant]
Cadet et al., “Neurotoxicity of Substituted Amphetamines: Molecular and Cellular Mechanisms,” Neurotoxicity Research, 2007, vol. 11, Nos. 3-4, pp. 183-202. [cited by applicant]
Cass et al., “HIV-1 protein Tat potentiation of methamphetamine-induced decreases in evoked overflow of dopamine in the striatum of the rat,” Brain Research, 2003, vol. 984, pp. 133-142. [cited by applicant]
Chan et al., “Pharmacotherapy for methamphetamine/amphetamine use disorder—a systematic review and meta-analysis,” Addiction, 2019, vol. 114, pp. 2122-2136. [cited by applicant]
Chang et al., “Structural and metabolic brain changes in the striatum associated with methamphetamine abuse,” Addiction, 2007, vol. 102, Suppl. 1, pp. 16-32. [cited by applicant]
Choi et al., “Directional control of surface plasmon polariton waves propagating through an asymmetric Bragg resonator,” Applied Physics Letters, 2009, vol. 94, p. 063115. [cited by applicant]
Coffin et al., “Aripiprazole for the treatment of methamphetamine dependence: A randomized, double-blind, placebo-controlled trial,” Addiction, Apr. 2013, vol. 108, No. 4, pp. 751-761. [cited by applicant]
Coffin et al., “Extended-Release Naltrexone for Methamphetamine Dependence among Men Who Have Sex with Men: A Randomized Placebo-Controlled Trial,” Addiction, Feb. 2018, vol. 113, No. 2, pp. 268-278. [cited by applicant]
Colfax et al., “Mirtazapine to Reduce Methamphetamine Use: A Randomized Controlled Trial,” Archives of General Psychiatry, Nov. 2011, vol. 68, No. 11, pp. 1168-1175. [cited by applicant]
Croissant et al., “Nanovalve-Controlled Cargo Release Activated by Plasmonic Heating,” Journal of the American Chemical Society, 2012, vol. 134, pp. 7628-7631. [cited by applicant]
Del Guerra et al., “Human immunodeficiency virus-associated depression: contributions of immuno-inflammatory, monoaminergic, neurodegenerative, and neurotrophic pathways,” Journal of Neurovirology, 2013, vol. 19, pp. 31… [cited by applicant]
Desai et al., “Identification of a Dopamine Transporter Ligand That Blocks the Stimulant Effects of Cocaine,” The Journal of Neuroscience, Feb. 23, 2005, vol. 25, No. 8, pp. 1889-1893. [cited by applicant]
Dittrich et al., “COR-ART: A multicenter, randomized, double-blind, placebo-controlled dose-ranging study to evaluate single oral doses of vanoxerine for conversion of recent-onset atrial fibrillation or flutter to norm… [cited by applicant]
Doyle et al., “Aging, Prospective Memory, and Health-Related Quality of Life in HIV Infection,” AIDS and Behavior, 2012, vol. 16, pp. 2309-2318. [cited by applicant]
Droutman et al., “Neurocognitive decision-making processes of casual methamphetamine users,” NeuroImage: Clinical, 2019, vol. 21, p. 101643. [cited by applicant]
Elkashef et al., “Bupropion for the Treatment of Methamphetamine Dependence,” Neuropsychopharmacology, 2008, vol. 33, pp. 1162-1170. [cited by applicant]
Elkashef et al., “Topiramate for the treatment of methamphetamine addiction: a multi-center placebo-controlled trial,” Addiction, Jul. 2012, vol. 107, No. 7, pp. 1297-1306. [cited by applicant]